GE HealthCare announces CE Mark for the new digital 4D SPECT/CT system, StarGuide GX

GE HealthCare announced CE Mark for its StarGuide GX a new digital 4D SPECT/CT system designed with excellent precision, clinical efficiency and impressive versatility. This milestone marks a significant moment in molecular imaging’s evolution, helping empower clinicians to expand research and help personalize care across a growing range of nuclear medicine applications and tracers – including the acquisition of alpha emitters.

StarGuide GX comes at a pivotal time for the field of nuclear medicine. As complex diseases such as cancer, Alzheimer’s and cardiovascular disease become increasingly prevalent, the demand for precision diagnostics and targeted therapies is accelerating. StarGuide GX helps meet this need head-on, enabling clinicians to break free from energy-range limitations and image tracers with exceptional clarity. With growing demand for digital SPECT/CT – partially driven by the rise of theranostics – GE HealthCare’s innovation arrives as departments seek all-in-one, scalable solutions to help manage increasing patient volumes and complex treatment protocols.

“Our mission is to advance precision health by delivering technologies that meet the evolving needs of clinicians and patients,” shares Jean-Luc Procaccini, President and CEO, Molecular Imaging and Computed Tomography, GE HealthCare. “As nuclear medicine evolves to meet the demands of precision health, StarGuide GX is designed to help researchers and clinicians stay ahead, offering a whole new range of possibilities with one scanner. This innovation reflects our commitment to purposeful technology – supporting cases across care pathways and the practice of theranostics – to help both expand clinical capabilities and improve outcomes for patients worldwide.”

“StarGuide GX is an innovation sure to prove valuable now and in the future,” says Erez Levy, Executive Director, Molecular Imaging, GE HealthCare. “Its ability to image alpha emitters and deliver accurate quantitation in short scan times could create new opportunities for clinicians to personalize treatment with great confidence. This technology holds the promise of expanding nuclear medicine’s research capabilities and clinical practice – with the ultimate goal of improving outcomes for patients across a wide range of conditions.”